Home / Innere Medizin / Breakfast Brief Dr. Solange Peters

Breakfast Brief Dr. Solange Peters

Prof. Solange Peters presents the newest data on immunotherapy in NSCLC.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten

Prof. Solange Peters, head of the Medical Oncology Service, Chair of Thoracic Oncology, Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, presents the newest data on immunotherapy in NSCLC.

Abstracts presented:
Kowanetz M et al., abstract CT076:  IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups
Gandhi L et al., abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC
Hellmann MD et al., abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227
Forde PM et al., abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer